Research Papers:
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2672 views | HTML 4653 views | ?
Abstract
Massimo Milione1, Elena Ardini2, Jason Christiansen3, Emanuele Valtorta4, Silvio Veronese4, Roberta Bosotti2, Alessio Pellegrinelli1, Adele Testi1, Filippo Pietrantonio5, Giovanni Fucà6, Ge Wei3, Danielle Murphy3, Salvatore Siena4,5, Antonella Isacchi2 and Filippo De Braud5,6
11st Division of Pathology, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
2Nerviano Medical Sciences S.r.l., Milan, Italy
3Ignyta, Inc., San Diego, CA, United States of America
4Division of Pathology, Department of Laboratory Medicine, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
5Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy
6Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Correspondence to:
Massimo Milione, email: [email protected]
Keywords: NTRK1, TRKA, entrectinib, CRC, rearrangement
Received: April 12, 2017 Accepted: July 12, 2017 Published: July 24, 2017
ABSTRACT
In colorectal cancer patients, chromosomal rearrangements involving NTRK1 gene (encoding the TRKA protein) are shown in a small subset of patients and are associated with the constitutive activation of the kinase domain of TRKA. In turn, activated TRKA-fusion proteins are associated with proliferation and survival in colorectal cancer tumors.
Here we report the identification and functional characterization of a new SCYL3-NTRK1 fusion gene in a 61-year-old colorectal cancer patient. To our knowledge, this fusion protein has never been previously documented in oncological patients. We show that this novel fusion is oncogenic and sensitive to TRKA inhibitors.
As suggested by other pieces of evidence, entrectinib - an orally available pan-TRK, ROS1 and ALK inhibitor - may have particular efficacy in patients with NTRK rearrangements. Therefore, screening for rearrangements involving NTRK genes may help identifying a subset of patients able to derive benefit from treatment with entrectinib or other targeted inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19512